Artiva Biotherapeutics

Artiva Biotherapeutics announces full year 2024 financial results and recent business highlights. We’re excited to share our progress in 2024, including strengthening key leadership with cell therapy and autoimmune expertise across the organization. As we look ahead, we're energized by the opportunities 2025 holds and remain focused on advancing our mission. Read the full release here: https://lnkd.in/gH-FYfJM #ARTV #AlloNK #NKcell #NKcells #NKcelltherapy #clinicaltrials #autoimmunedisease #autoimmunity #immunology #autoimmune #lupus #lupusnephritis

How is Artiva pairing ?????????????????? and ?????????? to transform treatment for autoimmune diseases? As President and CEO Fred Aslan tells ?????? ?????? ???????????? host Daniel Levine, Artiva is leveraging the proven ability of already approved monoclonal antibodies (mAbs) to target disease-driving cells and to deliver a cytotoxic AlloNK? cell payload to eliminate them—with an off-the-shelf therapy that offers a better tolerability profile. In this way, Artiva hopes to bring the power of NK cell therapy in terms of its activity, but in an accessible format that looks a lot more like traditional biologics, he states.? ???Listen to the full podcast to learn more: https://lnkd.in/gb9DbdSv #AlloNK #NKcells #NKcelltherapy #clinicaltrials #autoimmunedisease #autoimmunity #immunology #autoimmune #lupus #lupusnephritis #cancer #oncology #BioReport

Did you know that autoimmunity is now one of the most common disease categories, ahead of cancer and heart disease? March is Autoimmune Awareness Month, a time to shine a light on the 100+ autoimmune diseases impacting over 50 million people in the US and countless others worldwide. Learn more at Autoimmune Association: https://lnkd.in/eJY_g7TH #AutoimmuneAwarenessMonth #autoimmunediseases #AlloNK #NKcell #NKcells #NKcelltherapy #clinicaltrials #autoimmunedisease #autoimmunity #immunology #autoimmune #lupus #lupusnephritis

Artiva Biotherapeutics will be presenting at the TD Cowen 45th Annual Health Care Conference on March 5 at 2:30 p.m. EST in Boston. Our leadership team will discuss the latest advancements in NK cell therapy for autoimmune diseases. See more details in the press release, including a link to the webcast to watch live or via replay: https://lnkd.in/gdXdsfhu #ARTV #AlloNK #NKcell #NKcells #NKcelltherapy #clinicaltrials #autoimmunedisease #autoimmunity #immunology #autoimmune #lupus #lupusnephritis

We are looking forward to the ???????? ???????????? ???????????? ???????????? ???????????? taking place March 3-5 in San Diego. We will have multiple presentations and panels to discuss the latest in NK cells in autoimmune disease, scalable manufacturing, and clinical advancements. ?? Monday, March 3 ??9am Panel: ?????????????????? ?????????????? & ???????????? ?????????????????????????? ???? ???????????????? ?????? ???????????????????? ?????????? ???? ???? ???? ?????????????????? with Fred Aslan ??10am Talk: ?????? ???? ?????????? ???????????? ?????????? ???????????????????? ???? ???????????????????? ??????????????? with Fred Aslan ??11am Roundtable: ???????????????????? ?????? ?????????????????????? ???? ???? ?????????? ???? ???? ???????????????????? ?????????????? with Heather Raymon, PhD ??1:30pm Talk: ?????????????????????????? ???????????????????? ???????????? ???? ?????????????????? ???? ???????????????????? ?????????? with Heather Raymon, PhD ?? Wednesday, March 5 ??8:30am Panel: ???????????????? ???? ?????????????????????????? ?????????????????? ?????? ???????????????????? ?????????????? ?????????????? & ???????????????????????? ?????????????? with Chris Horan ?? More details:? https://innate-killer.com/ #AlloNK #NKcell #NKcells #NKcelltherapy #clinicaltrials #autoimmunedisease #autoimmunity #immunology #autoimmune #lupus #lupusnephritis?

Artiva’s CEO Fred Aslan explores how Artiva is reshaping cell therapy with In Vivo’s David Wild. Unlike CAR-T therapies, Artiva’s AlloNK offers the potential for outpatient administration with an off-the-shelf therapy that is more accessible and offers a better tolerability profile. With a bold expansion into clinical trials in autoimmune diseases, Artiva is at the forefront of the next wave in cell therapy innovation. Read the full article here on Citeline (subscription may be required): https://lnkd.in/ga7chwde #CellTherapy #NKCells #AutoimmuneDisease #AlloNK

Artiva’s CEO Fred Aslan explores how Artiva is reshaping cell therapy with In Vivo’s David Wild. Unlike CAR-T therapies, Artiva’s AlloNK offers the potential for outpatient administration with an off-the-shelf therapy that is more accessible and offers a better tolerability profile. With a bold expansion into clinical trials in autoimmune diseases, Artiva is at the forefront of the next wave in cell therapy innovation. Read the full article here on Citeline (subscription may be required): https://lnkd.in/ga7chwde #CellTherapy #NKCells #AutoimmuneDisease #AlloNK

We are excited to announce the appointment of Dan Baker, M.D., to Artiva’s Board of Directors. Dr. Baker brings decades of experience in clinical development and regulatory strategy, including leading programs for important autoimmune therapies including Remicade?, Simponi?, and Stelara?. Dr. Baker’s expertise will be invaluable in driving the development of our AlloNK? cell therapies for autoimmune diseases. Read more here: https://lnkd.in/gTg7T8Kj #AlloNK #NKcell #NKcells #NKcelltherapy #clinicaltrials #autoimmunedisease #autoimmunity #immunology #autoimmune #lupus #lupusnephritis

At Artiva Biotherapeutics, we're dedicated to advancing the potential of allogeneic natural killer (NK) cell therapies with our manufacturing-first approach. In this PharmaVoice article, our CEO Fred Aslan explores how NK cells offer unique advantages over CAR-T therapies – combining scalability, cost-effectiveness, and potential safety advantages – and how Artiva is leading the way in bringing these therapies to patients worldwide. Dive into the full story here: https://lnkd.in/eTasuxFi #AlloNK #NKcells #NKcelltherapy #clinicaltrials #autoimmunedisease #autoimmunity #immunology #autoimmune #lupus #lupusnephritis?

What's in store in 2025 for cell therapy? Artiva Chief Technical Operations Officer, Chris Horan, shared his predictions in this podcast with Erin Harris of Cell & Gene. Among them, he foresees:? ?? an increased focus on the safety of cellular therapies ?? an expansion beyond oncology into other settings, such as autoimmune diseases ?? a rise in the development of allogeneic cell-based therapies? ?? a growing desire for accessible, easy-to-administer treatments? ?? improvements in manufacturing processes, scalability, and robustness? As for Artiva's roadmap, he mentioned a global expansion of clinical trials of the off-the-shelf, non-genetically modified AlloNK? cell therapy. ??? Listen to the full interview on Cell & Gene: The Podcast for more: https://lnkd.in/gitqTKaP #AlloNK #NKcell #NKcells #NKcelltherapy #clinicaltrials #autoimmunedisease #autoimmunity #immunology #autoimmune #lupus #lupusnephritis #celltherapy